Albert Barrios
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Albert Barrios has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Rajan Singh
Division of Endocrinology and Metabolism, College of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90747, USA
2 shared publications Bruce Witthuhn
Center for Mass Spectrometry and Proteomics, University of Minnesota, Minneapolis, MN
1 shared publication- Douglas Yee
Masonic Cancer Center, University of Minnesota, Minneapolis, MN
1 shared publication Golnaz Dirakvand
1 shared publication- Golnaz Dirakvand
Department of Biology, California State University, Dominguez Hills, Los Angeles, CA 90747, USA
1 shared publication Jacob Wragge
Center for Mass Spectrometry and Proteomics, University of Minnesota, Minneapolis, MN
1 shared publication
Latest Publications
- Open Access
- 15 February 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (4_Suppleme) , P2-03
Abstract P2-03-02: Detection of insulin receptor isoforms by mass spectrometry in breast cancer
Breast cancer cells express Type 1 Insulin-like Growth Factor Receptor (IGF1R) and Insulin Receptor (IR). These receptors have a role in breast cancer biology and mediate metabolism, proliferation, survival, and motility. IR gene undergoes differential splicing that generates two IR isoforms, IRA (exclusion of exon 11) and IRB. High levels of IRA expression in prenatal growth and development are observed, whereas IRB expression is more highly expressed in adult insulin responsive tissues. IRA overexpression is the predominant receptor isoform expressed in breast cancer specimens obtained from patients with endocrine resistant disease. To measure levels of IRA and IRB mRNA expression, we utilized IR isoform specific primers in quantitative reverse transcription PCR (qRT-PCR). The validation of IRA and IRB primers was determined via using IRA and IRB overexpressing clones of MCF7 cells. IRA and IRB mRNA expression was also studied in human adipose and liver tissues that majorly express the adult IRB isoform. Over 40 breast cancer cell lines and 20 ER+ patient tumor samples were studied to determine IRA and IRB mRNA expression. Total IR, IGF1R, IRS1, and IRS2 were also analyzed in cell lines and patient samples. Across the ATCC breast cancer cell lines and ER+ patient tumors, heterogeneity was found among all targeted genes. Using MCF-7 cells as control, we found one of the breast cancer cell lines, Du4475, has very high IRA mRNA expression level (200-fold of that in MCF-7). Using mass spectrometry technology, we quantified levels of IR isoform expression in Du4475 cells. Briefly, IR immunoprecipitates were subjected to SDS-PAGE gels and the IRA protein gel band was submitted for mass spectrometry. Since IRA does not contain exon 11, the identified unique peptide consistent with its expression is TFEDYLHNVVFVPRPS. After this IRA specific peptide was determined, the heavy-labeled (C13- and N15-containing) IRA peptide was used as an internal injection control to quantify the IRA level. Quantitative results of IRA peptode sequence were proportional to the mRNA levels previously detected in Du4475 cell lysate. Using MCF-7 IRB overexpression cell line MCF7L-IRB-C5, we identified two IRB peptides, KTSSGTGAEDPRPSR and TSSGTGAEDPRPSR at exon 11 region by mass spectrometry. Cell membrane and total cell lysates could also be used to detect IR protein isoforms by mass spectrometry analysis. Further measurement of IRA and IRB level on other breast cancer cell lines is ongoing. In summary, we are the first to use mass spectrometry to validate protein expression of IR isoforms at levels that correlate with mRNA expression. IRA mRNA and protein expression levels in breast cancer cell lines may serve as biomarkers to screen patients for targeted therapy. Citation Format: Xihong Zhang, LeeAnn Higgins, Todd Markowski, Tzu-Yi Yang, Jacob Wragge, Kevin Murray, Bruce Witthuhn, Albert Barrios, Douglas Yee. Detection of insulin receptor isoforms by mass spectrometry in breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-03-02.
- 15 February 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (4_Suppleme) , P2-03
Open AccessAbstract P2-03-02: Detection of insulin receptor isoforms by mass spectrometry in breast cancer
Breast cancer cells express Type 1 Insulin-like Growth Factor Receptor (IGF1R) and Insulin Receptor (IR). These receptors have a role in breast cancer biology and mediate metabolism, proliferation, survival, and motility. IR gene undergoes differential splicing that generates two IR isoforms, IRA (exclusion of exon 11) and IRB. High levels of IRA expression in prenatal growth and development are observed, whereas IRB expression is more highly expressed in adult insulin responsive tissues. IRA overexpression is the predominant receptor isoform expressed in breast cancer specimens obtained from patients with endocrine resistant disease. To measure levels of IRA and IRB mRNA expression, we utilized IR isoform specific primers in quantitative reverse transcription PCR (qRT-PCR). The validation of IRA and IRB primers was determined via using IRA and IRB overexpressing clones of MCF7 cells. IRA and IRB mRNA expression was also studied in human adipose and liver tissues that majorly express the adult IRB isoform. Over 40 breast cancer cell lines and 20 ER+ patient tumor samples were studied to determine IRA and IRB mRNA expression. Total IR, IGF1R, IRS1, and IRS2 were also analyzed in cell lines and patient samples. Across the ATCC breast cancer cell lines and ER+ patient tumors, heterogeneity was found among all targeted genes. Using MCF-7 cells as control, we found one of the breast cancer cell lines, Du4475, has very high IRA mRNA expression level (200-fold of that in MCF-7). Using mass spectrometry technology, we quantified levels of IR isoform expression in Du4475 cells. Briefly, IR immunoprecipitates were subjected to SDS-PAGE gels and the IRA protein gel band was submitted for mass spectrometry. Since IRA does not contain exon 11, the identified unique peptide consistent with its expression is TFEDYLHNVVFVPRPS. After this IRA specific peptide was determined, the heavy-labeled (C13- and N15-containing) IRA peptide was used as an internal injection control to quantify the IRA level. Quantitative results of IRA peptode sequence were proportional to the mRNA levels previously detected in Du4475 cell lysate. Using MCF-7 IRB overexpression cell line MCF7L-IRB-C5, we identified two IRB peptides, KTSSGTGAEDPRPSR and TSSGTGAEDPRPSR at exon 11 region by mass spectrometry. Cell membrane and total cell lysates could also be used to detect IR protein isoforms by mass spectrometry analysis. Further measurement of IRA and IRB level on other breast cancer cell lines is ongoing. In summary, we are the first to use mass spectrometry to validate protein expression of IR isoforms at levels that correlate with mRNA expression. IRA mRNA and protein expression levels in breast cancer cell lines may serve as biomarkers to screen patients for targeted therapy. Citation Format: Xihong Zhang, LeeAnn Higgins, Todd Markowski, Tzu-Yi Yang, Jacob Wragge, Kevin Murray, Bruce Witthuhn, Albert Barrios, Douglas Yee. Detection of insulin receptor isoforms by mass spectrometry in breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-03-02.
- Open Access
Human Brown Adipose Tissue and Metabolic Health: Potential for Therapeutic Avenues
Obesity-associated metabolic abnormalities comprise a cluster of conditions including dyslipidemia, insulin resistance, diabetes and cardiovascular diseases that has affected more than 650 million people all over the globe. Obesity results from the accumulation of white adipose tissues mainly due to the chronic imbalance of energy intake and energy expenditure. A variety of approaches to treat or prevent obesity, including lifestyle interventions, surgical weight loss procedures and pharmacological approaches to reduce energy intake and increase energy expenditure have failed to substantially decrease the prevalence of obesity. Brown adipose tissue (BAT), the primary source of thermogenesis in infants and small mammals may represent a promising therapeutic target to treat obesity by promoting energy expenditure through non-shivering thermogenesis mediated by mitochondrial uncoupling protein 1 (UCP1). Since the confirmation of functional BAT in adult humans by several groups, approximately a decade ago, and its association with a favorable metabolic phenotype, intense interest on the significance of BAT in adult human physiology and metabolic health has emerged within the scientific community to explore its therapeutic potential for the treatment of obesity and metabolic diseases. A substantially decreased BAT activity in individuals with obesity indicates a role for BAT in the setting of human obesity. On the other hand, BAT mass and its prevalence correlate with lower body mass index (BMI), decreased age and lower glucose levels, leading to a lower incidence of cardio-metabolic diseases. The increased cold exposure in adult humans with undetectable BAT was associated with decreased body fat mass and increased insulin sensitivity. A deeper understanding of the role of BAT in human metabolic health and its interrelationship with body fat distribution and deciphering proper strategies to increase energy expenditure, by either increasing functional BAT mass or inducing white adipose browning, holds the promise for possible therapeutic avenues for the treatment of obesity and associated metabolic disorders.
Open AccessHuman Brown Adipose Tissue and Metabolic Health: Potential for Therapeutic Avenues
Obesity-associated metabolic abnormalities comprise a cluster of conditions including dyslipidemia, insulin resistance, diabetes and cardiovascular diseases that has affected more than 650 million people all over the globe. Obesity results from the accumulation of white adipose tissues mainly due to the chronic imbalance of energy intake and energy expenditure. A variety of approaches to treat or prevent obesity, including lifestyle interventions, surgical weight loss procedures and pharmacological approaches to reduce energy intake and increase energy expenditure have failed to substantially decrease the prevalence of obesity. Brown adipose tissue (BAT), the primary source of thermogenesis in infants and small mammals may represent a promising therapeutic target to treat obesity by promoting energy expenditure through non-shivering thermogenesis mediated by mitochondrial uncoupling protein 1 (UCP1). Since the confirmation of functional BAT in adult humans by several groups, approximately a decade ago, and its association with a favorable metabolic phenotype, intense interest on the significance of BAT in adult human physiology and metabolic health has emerged within the scientific community to explore its therapeutic potential for the treatment of obesity and metabolic diseases. A substantially decreased BAT activity in individuals with obesity indicates a role for BAT in the setting of human obesity. On the other hand, BAT mass and its prevalence correlate with lower body mass index (BMI), decreased age and lower glucose levels, leading to a lower incidence of cardio-metabolic diseases. The increased cold exposure in adult humans with undetectable BAT was associated with decreased body fat mass and increased insulin sensitivity. A deeper understanding of the role of BAT in human metabolic health and its interrelationship with body fat distribution and deciphering proper strategies to increase energy expenditure, by either increasing functional BAT mass or inducing white adipose browning, holds the promise for possible therapeutic avenues for the treatment of obesity and associated metabolic disorders.
- Open Access
- 1 October 2021
- Published by MDPI AG in Preprints.org
Human Brown Adipose Tissue and Metabolic Health: Potential for Therapeutic Avenues
Obesity-associated metabolic abnormalities comprise of a cluster of conditions including dyslipidemia, insulin resistance, diabetes, and cardiovascular diseases that has affected more than 650 million people all over the globe. Obesity results from accumulation of white adipose tissues mainly due to the chronic imbalance of energy intake and energy expenditure. Variety of approaches to treat or prevent obesity, including lifestyle interventions, surgical weight loss procedures and pharmacological approaches to reduce energy intake and increase energy expenditure have failed to substantially decrease the prevalence of obesity. Brown adipose tissue (BAT), the primary source of thermogenesis in infants and small mammals may represent a promising therapeutic target to treat obesity by promoting energy expenditure through non-shivering thermogenesis mediated by mitochondrial uncoupling protein 1 (UCP1). Since the confirmation of functional BAT in adult humans by several groups, approximately a decade ago and its association with a favorable metabolic phenotype, intense interest on the significance of BAT in adult human physiology and metabolic health has emerged within the scientific community to explore its therapeutic potential for the treatment of obesity and metabolic diseases. Substantially decreased BAT activity in individuals with obesity indicates a role for BAT in setting of human obesity. On the other hand, BAT mass and its prevalence has been reported to correlate with lower body mass index (BMI), decreased age and glucose levels, leading to lower incidence of cardio metabolic diseases. Increased cold exposure in adult humans with undetectable BAT was associated with decreased body fat mass and increased insulin sensitivity. Deeper understanding of the role of BAT in human metabolic health and its inter-relationship with body fat distribution and deciphering proper strategies to increase energy expenditure by either increasing functional BAT mass, or inducing white adipose browning holds the promise for possible therapeutic avenues for the treatment of obesity and associated metabolic disorders.
- 1 October 2021
- Published by MDPI AG in Preprints.org
Open AccessHuman Brown Adipose Tissue and Metabolic Health: Potential for Therapeutic Avenues
Obesity-associated metabolic abnormalities comprise of a cluster of conditions including dyslipidemia, insulin resistance, diabetes, and cardiovascular diseases that has affected more than 650 million people all over the globe. Obesity results from accumulation of white adipose tissues mainly due to the chronic imbalance of energy intake and energy expenditure. Variety of approaches to treat or prevent obesity, including lifestyle interventions, surgical weight loss procedures and pharmacological approaches to reduce energy intake and increase energy expenditure have failed to substantially decrease the prevalence of obesity. Brown adipose tissue (BAT), the primary source of thermogenesis in infants and small mammals may represent a promising therapeutic target to treat obesity by promoting energy expenditure through non-shivering thermogenesis mediated by mitochondrial uncoupling protein 1 (UCP1). Since the confirmation of functional BAT in adult humans by several groups, approximately a decade ago and its association with a favorable metabolic phenotype, intense interest on the significance of BAT in adult human physiology and metabolic health has emerged within the scientific community to explore its therapeutic potential for the treatment of obesity and metabolic diseases. Substantially decreased BAT activity in individuals with obesity indicates a role for BAT in setting of human obesity. On the other hand, BAT mass and its prevalence has been reported to correlate with lower body mass index (BMI), decreased age and glucose levels, leading to lower incidence of cardio metabolic diseases. Increased cold exposure in adult humans with undetectable BAT was associated with decreased body fat mass and increased insulin sensitivity. Deeper understanding of the role of BAT in human metabolic health and its inter-relationship with body fat distribution and deciphering proper strategies to increase energy expenditure by either increasing functional BAT mass, or inducing white adipose browning holds the promise for possible therapeutic avenues for the treatment of obesity and associated metabolic disorders.